Analyst Ratings For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Today, Oppenheimer reiterated its Hold rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX).
There are 5 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Buy with a consensus target price of $5.20 per share, a potential 100.00% upside.
Some recent analyst ratings include
- 8/3/2018-Oppenheimer Reiterated Rating of Hold.
- 8/2/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 10/27/2017-HC Wainwright Reiterated Rating of Buy.
- 10/13/2017-Piper Jaffray Companies Reiterated Rating of Hold.
- 10/13/2017-Jefferies Financial Group was Downgraded by analysts at Jefferies Financial Group from a “Buy ” rating to a ” Hold” rating. They now have a N/A price target on the stock.
Recent Insider Trading Activity For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has insider ownership of 25.50% and institutional ownership of 8.40%.
- On 6/5/2018 Mark G Edwards, Director, bought 5,000 with an average share price of $3.35 per share and the total transaction amounting to $16,750.00.
- On 6/1/2018 Mark G Edwards, Director, bought 300 with an average share price of $3.30 per share and the total transaction amounting to $990.00.
- On 5/25/2018 Raffi Asadorian, CFO, bought 5,000 with an average share price of $3.18 per share and the total transaction amounting to $15,900.00.
- On 11/14/2017 Mark G Edwards, Director, bought 30,000 with an average share price of $1.90 per share and the total transaction amounting to $57,000.00.
- On 11/13/2017 Raffi Asadorian, CFO, bought 5,000 with an average share price of $1.94 per share and the total transaction amounting to $9,700.00.
- On 10/2/2017 Lawrence G Hamel, Insider, sold 10,161 with an average share price of $5.29 per share and the total transaction amounting to $53,751.69.
- On 9/11/2017 Raffi Asadorian, CFO, bought 7,000 with an average share price of $3.24 per share and the total transaction amounting to $22,680.00.
About AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Recent Trading Activity for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Shares of AcelRx Pharmaceuticals Inc closed the previous trading session at 2,60 −0,050 1,89 % with shares trading hands.
